DDInter396 DDInter1802
Clevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.
Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011.
Clevidipine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ticagrelor
Clevidipine {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Ticagrelor
Clevidipine {u} (Compound) resembles {v} (Compound) Nifedipine
Nifedipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Clevidipine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Nifedipine
Nifedipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Clevidipine {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Nifedipine
Nifedipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Clevidipine {u} (Compound) resembles {v} (Compound) Nifedipine
Nifedipine {u} (Compound) palliates {v} (Disease) coronary artery disease
coronary artery disease {u} (Disease) is treated by {v} (Compound) Ticagrelor
Clevidipine {u} (Compound) resembles {v} (Compound) Isradipine
Isradipine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ticagrelor
Clevidipine {u} (Compound) resembles {v} (Compound) Nitrendipine
Nitrendipine {u} (Compound) resembles {v} (Compound) Nisoldipine
Nisoldipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Clevidipine {u} (Compound) resembles {v} (Compound) Isradipine
Isradipine {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Unspecified disorder of skin and subcutaneous tissue {u} (Side Effect) is caused by {v} (Compound) Ticagrelor
Clevidipine {u} (Compound) causes {v} (Side Effect) Renal failure acute
Renal failure acute {u} (Side Effect) is caused by {v} (Compound) Clopidogrel
Clopidogrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ticagrelor
Clevidipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound)
Clevidipine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ticagrelor (Compound)
Clevidipine (Compound) resembles Nifedipine (Compound) and Nifedipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Clevidipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nifedipine (Compound) and Nifedipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Clevidipine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nifedipine (Compound) and Nifedipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Clevidipine (Compound) resembles Nifedipine (Compound) and Nifedipine (Compound) palliates coronary artery disease (Disease) and coronary artery disease (Disease) is treated by Ticagrelor (Compound)
Clevidipine (Compound) resembles Isradipine (Compound) and Isradipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound)
Clevidipine (Compound) resembles Nitrendipine (Compound) and Nitrendipine (Compound) resembles Nisoldipine (Compound) and Nisoldipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Clevidipine (Compound) resembles Isradipine (Compound) and Isradipine (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Ticagrelor (Compound)
Clevidipine (Compound) causes Renal failure acute (Side Effect) and Renal failure acute (Side Effect) is caused by Clopidogrel (Compound) and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor